📰 Human Use News
Page 107 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
October 31, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
October 28, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation...
October 28, 2022
EMA D120 Responses submitted in October as planned Two successful engineering batches of LUMEVOQ validate actions taken to correct low yields in previous runs €13.9 million of cash
October 28, 2022
Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT
October 27, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary, unaudited financial...
October 24, 2022
At the end of the latest market close, BioNTech SE (BNTX) was valued at $118.43. In that particular session, Stock kicked-off at the price of $122.00 while reaching the peak value of $131.85 and lowest value recorded on the day was $121.14. The stock current value is $131.64.Recently in News on Octo
October 21, 2022
An Australian study explored the predictive and prognostic ability of two PET imaging-based biomarkers to guide treatment with Novartis' radioligand therapy.
October 20, 2022
NEW YORK CITY (dpa-AFX) - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use or CHMP has recommended marketing authorization for a 3-microgram dose of COMIRNATY
October 19, 2022
NEW YORK and MAINZ, Germany, October 19, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended
October 19, 2022
Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and olderTwo-dose series